Compare NNVC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | NTRB |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 36.0M |
| IPO Year | 2008 | 2019 |
| Metric | NNVC | NTRB |
|---|---|---|
| Price | $1.24 | $4.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 249.8K | 23.5K |
| Earning Date | 05-15-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $2.80 |
| 52 Week High | $2.23 | $8.63 |
| Indicator | NNVC | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 34.38 | 69.45 |
| Support Level | $1.24 | $4.23 |
| Resistance Level | $1.29 | $4.98 |
| Average True Range (ATR) | 0.06 | 0.35 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 0.00 | 58.99 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.